621 related articles for article (PubMed ID: 23872509)
1. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
[TBL] [Abstract][Full Text] [Related]
2. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW
J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
6. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Ha SJ; Kim SJ; Hwang SJ; Woo JS; Kim W; Kim WS; Kim KS; Kim MK
Coron Artery Dis; 2013 Dec; 24(8):690-7. PubMed ID: 24152567
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
[TBL] [Abstract][Full Text] [Related]
8. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.
Kim JY; Lee K; Shin M; Ahn M; Choe H; Yoo BS; Yoon J; Choe KH; Lee SH
Circ J; 2007 Dec; 71(12):1867-72. PubMed ID: 18037738
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
Yang TH; Jin HY; Choi KN; Do U; Kim HJ; Chung SR; Seo JS; Jang JS; Kim DK; Kim DS
Int J Cardiol; 2013 Sep; 168(1):207-11. PubMed ID: 23106905
[TBL] [Abstract][Full Text] [Related]
10. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
Gao W; Zhang Q; Ge H; Guo Y; Zhou Z
Angiology; 2013 Oct; 64(7):554-8. PubMed ID: 23359782
[TBL] [Abstract][Full Text] [Related]
12. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
[TBL] [Abstract][Full Text] [Related]
13. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
Lee BK; Lee SW; Park SW; Lee SW; Park DW; Kim YH; Lee CW; Hong MK; Kim JJ; Jang S; Chi HS; Park SJ
Am J Cardiol; 2007 Aug; 100(4):610-4. PubMed ID: 17697815
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
Curr Med Res Opin; 2014 Jan; 30(1):37-49. PubMed ID: 24083626
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
Jang JS; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Kim DK; Seol SH; Kim DI; Cho KI; Kim BH; Park YH; Je HG; Jeong YH; Kim WJ; Lee JY; Lee SW
Cardiology; 2012; 122(3):133-43. PubMed ID: 22832424
[TBL] [Abstract][Full Text] [Related]
16. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
[TBL] [Abstract][Full Text] [Related]
17. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Chen KY; Rha SW; Li YJ; Poddar KL; Jin Z; Minami Y; Wang L; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
Circulation; 2009 Jun; 119(25):3207-14. PubMed ID: 19528339
[TBL] [Abstract][Full Text] [Related]
18. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
Gajos G; Rostoff P; Undas A; Piwowarska W
J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
[TBL] [Abstract][Full Text] [Related]
19. Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?
Niazi AK; Dinicolantonio JJ; Lavie CJ; O'Keefe JH; Meier P; Bangalore S
Cardiology; 2013; 126(4):233-43. PubMed ID: 24107485
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ
Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
